With this study, conventional and orally disintegrated tablets have been prepared with lurasidone hydrochloride as an active pharmaceutical ingredient. Process technologies of in-situ fluidized bed melt granulation, fluidized bed coating and tabletting have been used for preparation of tablets with good end-use properties. Excipients used in drug formulation are: mannitol, microcrystalline cellulose and lactose monohydrate as fillers; croscarmellose sodium as a disintegrant; magnesium stearate as a lubricant and polyethylene glycol 4000 Da as a binder. Disintegrant has been embedded in a tablet matrix using fluidized bed granulation and coating. Prepared tablet matrices are characterized by testing the mass, hardness and the disintegration of the tabs and by recording the drug release profiles. The effect of drug formulation and the way for embedding the disintegrant on the end-use properties of a tablet has been studied. Lurasidone release profiles from conventional and orally disintegrated tablets are analysed using DDSolver add-in program. Available models have been tested to describe the release profiles of LRD HCl. The drug release kinetics for LRD HCl from prepared tablet matrices is described with zero-order model with lag time prior to drug release and by Korsemeyer-Peppas model. Derived model exponents indicate the mechanisms for lurasidone release from the disintegrated tablet matrices.